SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending following its IPO, with the community actively discussing allocation strategies and potential volatility. Initial trading saw a halt, sparking debates about market manipulation and comparisons to other hyped IPOs. Bullish sentiment remains as traders speculate on the stock's potential, while others express concern over its balance sheet.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is experiencing a surge in community interest, potentially fueled by a recent tweet and anticipation of a "God candle." Discussions revolve around the stock's squeezability, the promise of future technologies, and the belief in nodules as a source of power. Some investors are closely monitoring technical indicators, while others await a headline catalyst.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma (ATYR) is trending amid anticipation for Phase 3 trial results, expected mid-September, with the community debating potential outcomes and impact on the company's pipeline. Discussions revolve around short squeeze potential, institutional ownership, and comparisons to other biotech firms facing binary events. Some traders are focused on options activity and hedging strategies, while others scrutinize analysts' price targets and historical accuracy.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated debates and political polarization following a shooting involving Charlie Kirk, with community members clashing over the shooter's motives and affiliations. Discussions involve broader issues of gun control, political extremism, and the release of the Epstein files. The community is also focused on the company's financial prospects and ties to Donald Trump.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as community members discuss the potential impact of the Black Widow drone system being added to the NATO Support and Procurement Agency (NSPA) catalogue, which could streamline acquisition processes and boost sales; the addition has sparked debates around revenue potential and comparisons with competitors like ONDS, with some investors expressing optimism for long-term growth due to government contracts and expansion into maritime vessels.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant volatility and a mixed sentiment among traders. The community is actively discussing the potential for a short squeeze and upcoming news related to a conference. Some traders express concerns about dilution and the stock's history, while others remain optimistic about its long-term potential, especially with news expected next week.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending as investors discuss its potential for a short squeeze, fueled by high short interest and a strong uptrend. Community members are pointing to potential catalysts and debating whether to take profits or hold, with many expressing bullish sentiment. The conversation also highlights the company's expansion into new areas like low testosterone treatments.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

X4 Pharmaceuticals (XFOR) on Wednesday announced the closing of an upsized private placement of over 11 million shares of common stock and pre-funded warrants to purchase nearly 49 million shares of common stock for total offering proceeds of $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-closing-upsized-85-million-private">said</a> that the originally announced offering of $60 million was increased to allow for the inclusion of an investor who had a pre-existing investment right.<a href="https://stocktwits.com/symbol/XFOR">X4</a> intends to use the net proceeds from the offering for continued development towards a potential additional approval of Mavorixafor in chronic neutropenia, in addition to the commercialization of the drug for the treatment of WHIM syndrome.On Stocktwits, retail sentiment around the stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_9_57_21_AM_png_cea6672fbd.webp" alt="XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="631" height="61"><figcaption>XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the placement and the additional funding.<stembedurl>https://stocktwits.com/Sir_Falstaff/message/624932917</stembedurl>However, another user opined that the stock would trade 200% higher if the news were that positive.<stembedurl>https://stocktwits.com/FreedoniaT/message/624925751</stembedurl>H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target for the XFOR stock to $3.50 from $7 and kept a ‘Buy’ rating on the shares, according to The Fly.The firm updated the company's model to reflect the second-quarter (Q2) report and the private placement. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst told investors in a research note.X4 on Tuesday announced that its President and Chief Executive Officer, Paula Ragan, and Chief Financial Officer Adam Mostafa have stepped down from their respective roles.X4 Board of Directors appointed Adam Craig as Executive Chair, John Volpone as President, and David Kirske as Chief Financial Officer, effective immediately.XFOR stock is down 86% this year and 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ppi-report-wall-street-awaits-wholesale-inflation-data-for-cues-fed-rate-cut/chrCQjNRd9J">PPI Report: Wall Street Awaits Wholesale Inflation Data For Further Cues On Fed’s Rate Path Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right.

Equity

X4 Pharmaceuticals Unveils Corporate Presentation for Investors

X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the pub...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options

Investors considering a purchase of X4 Pharmaceuticals Inc (XFOR) shares, but tentative about paying the going market price of 1.40/share, might benefit from considering selling puts among the...

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence

X4 Pharmaceuticals (XFOR) has disclosed a new risk, in the Share Price & Shareholder Rights category. X4 Pharmaceuticals currently faces the risk o...

Q4 2023 X4 Pharmaceuticals Inc Earnings Call Transcript

Recap: X4 Pharmaceuticals Q4 Earnings

X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05

X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05...

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and...

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.55	--	--	N/A
Q2 '25	-$3.37	--	--	N/A
Q1 '25	-$3.55	$0.04	101.13%	BEAT
Q4 '24	-$0.17	-$6.00	-3328.57%	MISSED
Q3 '24	-$0.17	-$0.18	-5.00%	MISSED

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest XFOR News

XFOR X4 Pharmaceuticals Inc